Feasibility of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention Deficit Disorder (ADD).

Using Combined Neuroimaging Techniques and Clinical Measures to Assess Feasibility of tDCS as an Intervention in Adult ADD.

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02206516

Acronym

BMST

Enrollment

Registered

2014-08-01

Start date

2014-07-31

Completion date

2018-09-30

Last updated

2018-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Attention Deficit Disorder

Brief summary

This study aims at combining imaging techniques and clinical evaluations to assess clinical change as well as brain changes that occur as a result of brain stimulation in adult attention deficit disorder.

Detailed description

This study will use clinical measures and cognitive tasks covering 3 different functional domains during functional magnetic resonance imaging (fMRI), ElectroEncephaloGram (EEG) and Ultrasound tagged near infrared spectroscopy (UT-NIRS), to assess functional brain changes as a result of a treatment protocol with Transcaranial direct current stimulation (tDCS) in adults suffering from attention deficit disorder (ADD).

Interventions

DEVICETranscranial Direct Current Stimulation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients between the ages of 18-65(male and female) 2. Diagnosed as suffering from Attention-Deficit Hyperactivity Disorder according to the DSM IV 3. Patients taking medication for ADHD will give their consent to stop those medication 48 before entering the study and throughout the daily treatments. 4. Gave informed consent for participation in the study 5. If referred by the treating psychiatrist, he or she approves of the subjects participation in the study

Exclusion criteria

1. Suffering from other diagnosis on axis 1 2. History of drug or alcohol abuse during the last year 3. Inability to achieve satisfying level of communication with the subject

Design outcomes

Primary

Measure	Time frame
Efficacy will be examined by the change in the CAARS questionnaire from the baseline visit to the determination visit in the treatment group compared to the control group.	6 weeks

Secondary

Measure	Time frame	Description
changes in functional activity after 4 weeks of tDCS treatment during response inhibition	6 weeks	ROI analysis of right Inferior frontal cortex will be measured during response inhibition in the Go/Nogo task at the end of the 4 weeks of treatment and will be compared to baseline measures.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026